Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001641172-25-020404
Filing Date
2025-07-21
Accepted
2025-07-21 16:30:23
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10443
2 EX-1 ex-1.htm EX-1 10214
  Complete submission text file 0001641172-25-020404.txt   22362
Mailing Address 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 MONTREAL A8 H4M 2X6
Business Address 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 MONTREAL A8 H4M 2X6 (514) 336-0444
Milestone Pharmaceuticals Inc. (Subject) CIK: 0001408443 (see all company filings)

EIN.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91001 | Film No.: 251137588
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3455 PEACHTREE ROAD NE, 5TH FLOOR ATLANTA GA 30326
Business Address 3455 PEACHTREE ROAD NE, 5TH FLOOR ATLANTA GA 30326 917-657-2249
Trails Edge Capital Partners, LP (Filed by) CIK: 0002077247 (see all company filings)

EIN.: 331689212 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G